erlotinib hydrochloride has been researched along with pyrimidine in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (pyrimidine) | Trials (pyrimidine) | Recent Studies (post-2010) (pyrimidine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 2,159 | 6 | 950 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatnagar, PK; Dastidar, SG; Kapoor, S; Nithya, D; Ray, A; Senthil, V; Sharma, A; Talwadkar, A; Tandon, R; Vali, S; Venkataramanan, R | 1 |
| Chen, HJ; Chen, KF; Chou, YC; Huang, JW; Kim, I; Liu, CY; Pao, KC; Shiau, CW; Su, JC | 1 |
2 other study(ies) available for erlotinib hydrochloride and pyrimidine
| Article | Year |
|---|---|
Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Computational Biology; Cyclin D1; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Membrane Potential, Mitochondrial; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1 | 2011 |
Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity.
Topics: Cell Line, Tumor; Cell Proliferation; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Phosphatase 2; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2012 |